Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 135 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 135 @ $71.5 vs 2 OI; Earnings 2/26 Before Open Ref=$346.69

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 213 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 213 @ $67.5 vs 2 OI; Earnings 2/26 Before Open Ref=$343.8

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 @ $67.5 vs 2 OI; Earnings 2/26 Before Open Ref=$343.8

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 @ $65.5 vs 2 OI; Earnings 2/26 Before Open Ref=$342.44

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Ask: 242 vs 2593 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Ask: 242 @ $55.5 vs 2593 OI; Earnings 2/26 Before Open Ref=$339.38

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls Sweep (45) near the Bid: 173 vs 2593 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls Sweep (45) near the Bid: 173 @ $56.034 vs 2593 OI; Earnings 2/26 Before Open Ref=$337.92

Madrigal Pharmaceuticals Option Alert: Mar 21 $320 Calls at the Ask: 923 vs 949 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Mar 21 $320 Calls at the Ask: 923 @ $36.0 vs 949 OI; Earnings 2/26 Before Open Ref=$335.69

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 99 vs 2484 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 99 @ $59.0 vs 2484 OI; Earnings 2/26 Before Open Ref=$338.91

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 100 vs 2394 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 100 @ $62.8 vs 2394 OI; Earnings 2/26 Before Open Ref=$340.52

Madrigal Pharmaceuticals Azioni (NASDAQ: MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Azioni

MADRIGAL PHARMACEUTICALS INC

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

News

Guidance

BDRX

Biodexa Pharmaceuticals Expects Initiation Of Phase 3 Registrational Study Of eRapa In FAP, Initiation Of IIT Of Tolimidone In T1D At University Of Alberta As 2025 Clinical Milestones

JP Morgan analyst David Karnovsky upgrades Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) from Neutral to Overweight and raises the price target from $30 to $34.

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Cinemark Holdings to Overweight, Raises Price Target to $34

Truist Securities analyst David Macdonald maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $375 to $385.

Truist Securities Maintains Buy on Cigna Group, Raises Price Target to $385

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">ePlus inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUS#NASDAQ">PLUS</a>)</h3>
<ul>
<li>On Feb. 5, ePlus lowered its FY25 revenue guidance. &#8220;Our third quarter results reflect the benefit of our investment in services and the continuing industry shift toward ratable, subscription and &#8216;as a service&#8217; revenue recognition,&#8221; said Mark Marron, president and CEO of ePlus. The company's stock fell around 11% over the past month and has a 52-week low of $53.83.</li>
<li>RSI Value: 27.4</li>
<li>PLUS Price Action: Shares of ePlus fell 2.6% to close at $57.84 on Thursday.</li>
<li>Edge Stock Ratings: 20.49 Momentum score with Value at 78.26. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/plus"><img loading="lazy" decoding="async" width="475" height="186" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054531/image-73.png" alt="" class="wp-image-867546" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054531/image-73.png 475w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054531/image-73-300x117.png 300w" sizes="(max-width: 475px) 100vw, 475px" /></a></figure>
<h3 class="wp-block-heading">Stanley Black &amp; Decker Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 7, HC Wainwright &amp; Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 29% over the past month and <a href="https://www.benzinga.com/quote/GNFT">has a 52-week low</a> of $53.91.</li>
<li>RSI Value: 26.6</li>
<li>SWK Price Action: Shares of Stanley Black &amp; Decker dipped 8.6% to close at $58.68 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0411">SWK stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0411"><img loading="lazy" decoding="async" width="915" height="802" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054644/image-74.png" alt="" class="wp-image-867554" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054644/image-74.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054644/image-74-300x263.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054644/image-74-768x673.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Himalaya Shipping Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>)</h3>
<ul>
<li>The company's stock fell around 19% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/HSHP">low of $4.29</a>.</li>
<li>RSI Value: 28.2</li>
<li>HSHP Price Action: Shares of Himalaya Shipping fell 3% to close at $4.46 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0411">HSHP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0411"><img loading="lazy" decoding="async" width="875" height="720" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054751/image-75.png" alt="" class="wp-image-867558" style="width:442px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054751/image-75.png 875w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054751/image-75-300x247.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11054751/image-75-768x632.png 768w" sizes="(max-width: 875px) 100vw, 875px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

HSHP

PLUS

Top 3 Industrials Stocks That May Explode In April

Truist Securities analyst David Macdonald maintains Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) with a Hold and lowers the price target from $6 to $5.5.

AVAH

Truist Securities Maintains Hold on Aveanna Healthcare Hldgs, Lowers Price Target to $5.5

JP Morgan analyst Mark Strouse downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Overweight to Neutral and lowers the price target from $14 to $7.

Downgrades

FLNC

JP Morgan Downgrades Fluence Energy to Neutral, Lowers Price Target to $7

Oppenheimer analyst Edward Yang maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and lowers the price target from $240 to $150.

ONTO

Oppenheimer Maintains Outperform on Onto Innovation, Lowers Price Target to $150

<ul>
<li>Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA&#xAE; (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. &nbsp;</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces the filing of two groundbreaking patents for tapinarof (VTAMA&#xAE;), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.

Conduit Pharma Files Next Generation Cocrystal Patent For VTAMA With Enhanced Therapeutic And Market Extension Prospects

Jefferies analyst Roger Song upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Hold to Buy and raises the price target from $1 to $2.

NKTR

Jefferies Upgrades Nektar Therapeutics to Buy, Raises Price Target to $2

Oppenheimer analyst Edward Yang maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Outperform and lowers the price target from $850 to $700.

KLAC

Oppenheimer Maintains Outperform on KLA, Lowers Price Target to $700

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>). The company will release earnings for the first quarter of 2025 on Tuesday, May 6, after <a href="https://www.benzinga.com/quote/ET/earnings">the closing bell</a>.
Cramer also said he likes Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). &#8220;I'd pull the trigger.&#8221; 
As per the recent news, Snowflake announced on Thursday that it received DOD IL5 Provisional Authorization on AWS GovCloud US-West. The authorization enables the company to offer solutions requiring the highest levels of protection for<a href="https://in.benzinga.com/25/04/44740624/snowflake-achieves-dod-il5-authorization-shares-move-lower-what-you-need-to-know"> Controlled Unclassified Information</a>.
The Mad Money host said this is a &#8220;fantastic chance&#8221; to buy Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>).
Supporting his view, JP Morgan analyst Jeremy Tonet maintained Enterprise Products Partners with an Overweight rating on March 27 and raised the price target from $37 to $38.
Cramer said no to Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>), adding that it is losing money.
On the earnings front, Applied Digital will host a conference call on Monday, April 14, to discuss its operations and financial results for the fiscal third quarter.
When asked about Peabody Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), Cramer said, &#8220;We got to be careful. It's not going to make us money.&#8221;
Peabody Energy, on Feb. 6, reported mixed fourth-quarter financial results.
Price Action:
<ul>
<li>Energy Transfer shares fell 4.6% to settle at $15.91 on Thursday.</li>
<li>Snowflake shares declined 4.4% to close at $144.45 during the session.</li>
<li>Enterprise Products Partners&#8217; shares fell 2.5% to settle at $28.95.</li>
<li>Peabody Energy shares dipped 8.4% to close at $11.23 on Thursday.</li>
<li>Applied Digital shares dipped 7.1% to settle at $5.13 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo: Shutterstock

Media

APLD

SNOW

Jim Cramer Likes Energy Transfer And Snowflake, Says Applied Digital Is Losing Money

Jefferies analyst Andrew Andersen downgrades Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) from Buy to Hold and lowers the price target from $62 to $59.

SKWD

Jefferies Downgrades Skyward Specialty to Hold, Lowers Price Target to $59

INTA

Intapp To Acquire TermSheet; Financial Terms Not Disclosed

PSEC

QCCO

Prospect Capital Corporation To Acquire QC Holdings For $2/Share In Cash

Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/GS/earnings">opening bell on Monday, April 14.</a>
Analysts expect the bank to report quarterly earnings at $12.35 per share, up from $11.58 per share in the year-ago period. Goldman Sachs projects to report quarterly revenue at $14.81 billion, compared to $14.21 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, JMP Securities analyst Devin Ryan maintained Goldman Sachs with a Market Outperform rating and lowered the price target from $625 to $600.
With the recent buzz around Goldman Sachs, some investors may be eyeing potential gains from the company's dividends too. Currently, Goldman Sachs offers an annual dividend yield of 2.45%. That&#8217;s a quarterly dividend of $3.00 per share ($12.00 annually).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $244,900 or around 500 shares. For a more modest $100 per month or $1,200 per year, you would need $48,980 or around 100 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($12.00 in this case). So, $6,000 / $12.00 = 500 ($500 per month), and $1,200 / $12.00 = 100 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
GS Price Action: Shares of Goldman Sachs fell 5.2% to close at $489.80 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Image: Shutterstock

Earnings

How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q1 Earnings

The Board of Directors of CSW Industrials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWI#NASDAQ">CSWI</a>) today declared a regular quarterly cash dividend of $0.27 per share. This represents an increase of $0.03 per share, or approximately 12.5%, as compared to the paid dividend in the prior quarter. The dividend is payable on May 9, 2025, to shareholders of record as of the close of business on April 25, 2025.

Dividends

CSWI

CSW Industrials Increases Quarterly Dividend From $0.24 To $0.27 Per Share

Jefferies analyst Andrew Andersen upgrades Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) from Hold to Buy and raises the price target from $376 to $415.

Jefferies Upgrades Everest Group to Buy, Raises Price Target to $415

Economics

PPI ex. Food/Energy/Transport (YoY) (Mar) +3.4%; +3.5% Prior

Macro Economic Events

Econ #s

USA Core PPI (MoM) For March -0.1% Vs 0.3% Est.; 0.1% Prior

Macro Notification

General

USA PPI (MoM) For March -0.4% Vs 0.2% Est.; 0.1Prior

Health Care

Press Releases

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
03:51 PMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	97	675	135	33750	2	TRADE	BEARISH
10:19 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	97	186	213	9300	2	TRADE	BEARISH
10:19 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	97	186	100	9300	2	TRADE	BEARISH
10:11 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	97	150	100	7500	2	TRADE	BEARISH
10:08 AMFeb 20, 2025	CALL	$300.00	Apr 17, 2025	5	263	242	10	2593	TRADE	BULLISH
10:07 AMFeb 20, 2025	CALL	$300.00	Apr 17, 2025	5	1	173	0	2593	SWEEP	BEARISH
03:11 PMFeb 19, 2025	CALL	$320.00	Mar 21, 2025	-22	185	923	19	949	TRADE	BULLISH
11:19 AMFeb 18, 2025	CALL	$300.00	Apr 17, 2025	5	104	99	4	2484	TRADE	BEARISH
03:01 PMFeb 14, 2025	CALL	$300.00	Apr 17, 2025	5	112	100	5	2394	TRADE	BEARISH

Comments

Madrigal Pharmaceuticals

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO